44 Result(s)
-
Article
Open AccessVein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection
An observational study involving patients recovered from COVID-19 was conducted in order to evaluate the presence/absence of vein wall thickness increasing, according to the severity of pulmonary involvement q...
-
Article
Open AccessComprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres
The current therapeutic algorithm for Advanced Stage Melanoma comprises of alternating lines of Targeted and Immuno-therapy, mostly via Immune-Checkpoint blockade. While Comprehensive Genomic Profiling of soli...
-
Article
Open AccessUpregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin
BRAF-mutant melanoma patients benefit from the combinatorial treatments with BRAF and MEK inhibitors. However, acquired drug resistance strongly limits the efficacy of these targeted therapies in time. Recentl...
-
Article
Open AccessCD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
Identifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma.
-
Article
Open AccessIL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. ...
-
Article
Open AccessConcomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization
The clinical observation showed a potential additive effect of anti-PD-1 agents and cetirizine in patients with advanced melanoma.
-
Article
Open AccessBasal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma
To evaluate the capability of basal and one-month differed white blood cells (WBC), neutrophil, lymphocyte and platelet values and their ratios (neutrophils-to-lymphocytes ratio, NLR, and platelets-to-lymphocy...
-
Article
Open AccessCorrection to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
-
Article
Open AccessImmunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis
Coronavirus disease 2019 (COVID-19) global pandemic has created unique challenges to healthcare systems throughout the world. Ensuring subjects’ safety is mandatory especially in oncology, in consideration of ...
-
Article
Open AccessCould asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave
-
Article
Open AccessAvelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program
The incidence of Merkel cell carcinoma (MCC), a rare form of skin cancer with a poor prognosis, has increased in Italy in recent decades. Avelumab, an anti-programmed death ligand 1 monoclonal antibody, is app...
-
Article
Open AccessThe clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic
COVID-19 pandemic following the outbreak in China and Western Europe, where it finally lost the momentum, is now devastating North and South America. It has not been identified the reason and the molecular mec...
-
Article
Open AccessTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.
-
Article
Open AccessAnti-IL6R role in treatment of COVID-19-related ARDS
-
Article
Open AccessCorrection to: New paradigm for stage III melanoma: from surgery to adjuvant treatment
Following publication of the original article [1], the authors reported that one of the authors, Corrado Caracò, has been accidentally omitted from the author list. In this Correction the author has been added...
-
Article
Open AccessNew paradigm for stage III melanoma: from surgery to adjuvant treatment
Recently the 8th version of the American Joint Committee on Cancer (AJCC) classification has been introduced, and has attempted to define a more accurate and precise definition of prognosis in line with the ma...
-
Article
Open AccessGermline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study
Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant melanoma (CMM). They are often sporadic harbouring several somatic mutations, but also familial cases harbouring a CDKN2A germl...
-
Article
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses that are induced by the combined inhibition of BRAF and MEK1. Here we performed a randomized phase 2 trial ( ...
-
Chapter
Melanoma
Melanoma is a malignant tumor that arises from melanocytic cells and primarily involves the skin. Early diagnosis is fundamental for surgical treatment of localized disease. A conservative surgical excision ap...
-
Article
Open AccessTargeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells
Accumulating evidence demonstrates that the Urokinase Receptor (uPAR) regulates tumor cell migration through its assembly in composite regulatory units with transmembrane receptors, and uPAR88–92 is the minimal s...
